谱尼测试(300887) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥571,055,553.05, a decrease of 42.78% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥12,042,267.87, down 86.63% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.0221, reflecting a decline of 87.08% compared to the previous year[5] - The company reported a significant drop in operating income for the first nine months of 2023, totaling ¥1,758,239,802.93, down 34.44% year-on-year[10] - The company experienced a 43.35% reduction in operating costs, amounting to ¥990,117,572.19 for the first nine months of 2023[10] - Total operating revenue for Q3 2023 was CNY 1,758,239,802.93, a decrease of 34.4% compared to CNY 2,681,962,616.87 in the same period last year[23] - Net profit for Q3 2023 was CNY 106,862,369.46, a decline of 41.7% compared to CNY 183,128,322.81 in Q3 2022[24] - Earnings per share for Q3 2023 were CNY 0.1931, down from CNY 0.3570 in the previous year[25] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥4,339,056,929.01, a decrease of 5.26% from the end of the previous year[5] - The company’s total liabilities decreased by 5.26% compared to the previous year, indicating improved financial stability[9] - As of September 30, 2023, total assets amounted to ¥4,339,056,929.01, a decrease from ¥4,579,931,494.76 at the beginning of the year[20] - Current assets decreased to ¥2,262,252,874.36 from ¥2,819,479,353.17, reflecting a decline of approximately 19.7%[21] - Total liabilities decreased to CNY 855,490,346.55 from CNY 1,028,704,755.20, reflecting a reduction of 16.8%[24] - Total equity attributable to shareholders was CNY 3,471,202,238.71, down from CNY 3,538,604,312.29, a decrease of 1.9%[24] Cash Flow - The company’s cash flow from operating activities for the first nine months was ¥97,066,416.16, down 68.21% year-on-year[5] - Operating cash inflow for the first nine months of 2023 was approximately ¥1.85 billion, a decrease of 27.95% compared to the same period in 2022 due to reduced demand for infectious disease testing services[12] - Operating cash outflow for the same period was approximately ¥1.75 billion, down 22.50% year-on-year, attributed to decreased procurement payments and lower personnel salaries[12] - Net cash flow from operating activities was approximately ¥97 million, reflecting a significant decline of 68.21% compared to ¥305 million in 2022[12] - The net cash flow from operating activities for Q3 2023 was ¥97,066,416.16, a decrease of 68.2% compared to ¥305,336,751.55 in Q3 2022[27] - The total cash outflow from operating activities was ¥1,750,227,548.02, compared to ¥2,258,468,639.20 in Q3 2022, indicating a reduction in cash outflow[27] Investment Activities - Investment income increased by 173.21% to ¥11,483,432.05, attributed to higher returns from financial products[10] - Investment cash inflow surged to approximately ¥3.16 billion, an increase of 330.94% year-on-year, primarily due to the redemption of financial products[12] - Investment cash outflow increased to approximately ¥3.29 billion, up 97.55% from the previous year, driven by higher cash payments for financial products and land purchases[12] - Net cash flow from investment activities was approximately -¥129 million, an improvement of 86.11% compared to -¥933 million in 2022[12] - The total cash inflow from investment activities was ¥3,164,223,972.73, significantly higher than ¥734,258,520.91 in the same period last year[27] - The net cash flow from investment activities was -¥129,632,459.26, improving from -¥933,074,841.11 year-over-year[27] Financing Activities - Financing cash inflow decreased to approximately ¥165 million, down 89.38% year-on-year, due to last year's fundraising activities[12] - Financing cash outflow was approximately ¥342 million, a decrease of 13.03% compared to the previous year, mainly due to reduced bank debt repayments[12] - Net cash flow from financing activities was approximately -¥178 million, reflecting a decline of 115.37% compared to the previous year[12] - Cash inflow from financing activities totaled ¥164,568,545.61, down from ¥1,549,223,001.44 in Q3 2022[27] - The net cash flow from financing activities was -¥177,652,644.69, compared to a positive cash flow of ¥1,155,745,879.45 in the previous year[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,796, with the top ten shareholders holding significant stakes[14] - The company reported a total of 184,994,578 shares under lock-up agreements, with 184,680,126 shares released during the period[18] - The company plans to unlock 30% of the first category incentive shares after 18 months, with subsequent unlocks of 30% and 40% at 30 and 42 months respectively[18] Research and Development - Research and development expenses for Q3 2023 were CNY 142,106,527.87, a reduction of 22.7% compared to CNY 183,814,721.27 in the previous year[24] Financial Management - The company reported a financial expense of CNY -1,914,237.74, compared to CNY 5,721,856.84 in the same period last year, indicating improved financial management[24] Audit Status - The company did not undergo an audit for the Q3 report, indicating it remains unaudited[28]